德州2+3

Huisheng News
You are here: Home > News > Corporate News
Corporate News
Huisheng Biological "Rifaximin Uterine Injection" Received National Five New Veterinary Drug Registration Certificates!
Release time: October 30, 2019Views: 324
On September 23, the Ministry of Agriculture and Rural Affairs of the People's Republic of China issued Announcement No. 214, which approved Hubei Huisheng Biotechnology Co., Ltd., Nanjing Agricultural University, Shandong Lukang Shelile Pharmaceutical Co., Ltd. High-tech Division, Foshan Nanhai Dongfang Aolong Pharmaceutical Co., Ltd., Sichuan Chuanlong Animal Science Pharmaceutical Co., Ltd., and Henan Yihua Animal Pharmaceutical Co., Ltd. jointly declared the "Lifford Ximing Uterine Injection is five types of new veterinary drugs, and issued the "New Veterinary Drug Registration Certificate", certificate number: (2019) New Veterinary Drug Certificate No. 63.

Rifaximin is a rifamycin derivative. It was developed by Italian company Alpha. It was launched in Italy in 1987 as an anti-infective diarrhea drug. It was approved by the SFDA in 2004 and has been used in China. It has the advantages of being difficult to be absorbed orally, safe, high efficiency, low residue, and no-drug period. Rifaximin uterine injection is mainly used to treat cow endometritis caused by susceptible bacteria such as staphylococcus, streptococcus, cryptococcus, escherichia coli and anaerobic bacteria.

Five new veterinary drugs "rifaximin uterine injection" are the results of joint development of Huisheng Biological and Nanjing Agricultural University. One is obtained through prescription process research, quality research, stability investigation, and clinical effect verification. And a suspension for treating cow's uterine inflammation.